» Articles » PMID: 26335440

Comparison of Tolerability and Adverse Symptoms in Oxcarbazepine and Carbamazepine in the Treatment of Trigeminal Neuralgia and Neuralgiform Headaches Using the Liverpool Adverse Events Profile (AEP)

Overview
Journal J Headache Pain
Publisher Biomed Central
Date 2015 Sep 4
PMID 26335440
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adverse effects of drugs are poorly reported in the literature . The aim of this study was to examine the frequency of the adverse events of antiepileptic drugs (AEDs), in particular carbamazepine (CBZ) and oxcarbazepine (OXC) in patients with neuralgiform pain using the psychometrically tested Liverpool Adverse Events Profile (AEP) and provide clinicians with guidance as to when to change management.

Methods: The study was conducted as a clinical prospective observational exploratory survey of 161 patients with idiopathic trigeminal neuralgia and its variants of whom 79 were on montherapy who attended a specialist clinic in a London teaching hospital over a period of 2 years. At each consultation they completed the AEP questionnaire which provides scores of 19-76 with toxic levels being considered as scores >45.

Results: The most common significant side effects were: tiredness 31.3 %, sleepiness 18.2 %, memory problems 22.7 %, disturbed sleep 14.1 %, difficulty concentrating and unsteadiness 11.6 %. Females reported significantly more side effects than males. Potential toxic dose for females is approximately 1200 mg of OXC and 800 mg of CBZ and1800mg of OXC and 1200 mg of CBZ for males.

Conclusions: CBZ and OXC are associated with cognitive impairment. Pharmacokinetic and pharmacodynamic differences are likely to be the reason for gender differences in reporting side effects. Potentially, females need to be prescribed lower dosages in view of their tendency to reach toxic levels at lower dosages. Side effects associated with AED could be a major reason for changing drugs or to consider a referral for surgical management.

Citing Articles

Nanomedicine and voltage-gated sodium channel blockers in pain management: a game changer or a lost cause?.

Le Franc A, Da Silva A, Lepetre-Mouelhi S Drug Deliv Transl Res. 2024; 14(8):2112-2145.

PMID: 38861139 DOI: 10.1007/s13346-024-01615-9.


Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review.

Naderi Y, Rad M, Sadatmoosavi A, Khaleghi E, Khorrami Z, Chamani G Clin Exp Dent Res. 2024; 10(2):e882.

PMID: 38558383 PMC: 10982606. DOI: 10.1002/cre2.882.


Efficiency and Efficacy of Real-Time Fluoroscopic Image-Guided Percutaneous Gasserian Glycerol Rhizotomy (PGGR), for Intractable Cases of Trigeminal Neuralgia.

Jeyaraj P J Maxillofac Oral Surg. 2023; 21(4):1053-1064.

PMID: 36896085 PMC: 9989047. DOI: 10.1007/s12663-021-01682-2.


Glutamatergic systems in neuropathic pain and emerging non-opioid therapies.

Temmermand R, Barrett J, Fontana A Pharmacol Res. 2022; 185:106492.

PMID: 36228868 PMC: 10413816. DOI: 10.1016/j.phrs.2022.106492.


Long term evaluation of a multidisciplinary trigeminal neuralgia service.

Singhota S, Tchantchaleishvili N, Wu J, Zrinzo L, Thorne L, Akram H J Headache Pain. 2022; 23(1):114.

PMID: 36057552 PMC: 9441024. DOI: 10.1186/s10194-022-01489-7.


References
1.
Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A . Quality of reporting in systematic reviews of adverse events: systematic review. BMJ. 2014; 348:f7668. PMC: 3898583. DOI: 10.1136/bmj.f7668. View

2.
Berger M, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand S . Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012; 15(2):217-30. DOI: 10.1016/j.jval.2011.12.010. View

3.
Nadkarni S, Devinsky O . Psychotropic effects of antiepileptic drugs. Epilepsy Curr. 2005; 5(5):176-81. PMC: 1201637. DOI: 10.1111/j.1535-7511.2005.00056.x. View

4.
Zakrzewska J, Bain B . Carbamazepine and folic acid in trigeminal neuralgia patients. J R Soc Med. 1992; 85(1):19-22. PMC: 1293455. DOI: 10.1177/014107689208500107. View

5.
Aldenkamp A, van Meel H, Baker G, Brooks J, Hendriks M . The A-B neuropsychological assessment schedule (ABNAS): the relationship between patient-perceived drug related cognitive impairment and results of neuropsychological tests. Seizure. 2002; 11(4):231-7. DOI: 10.1053/seiz.2002.0672. View